Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 196

1.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Ren R.

Nat Rev Cancer. 2005 Mar;5(3):172-83. Review.

PMID:
15719031
[PubMed - indexed for MEDLINE]
2.

Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.

Nimmanapalli R, Bhalla K.

Curr Opin Oncol. 2002 Nov;14(6):616-20. Review.

PMID:
12409651
[PubMed - indexed for MEDLINE]
3.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

PMID:
17317816
[PubMed - indexed for MEDLINE]
Free Article
4.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

PMID:
16204063
[PubMed - indexed for MEDLINE]
Free Article
5.

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Yoshida C, Melo JV.

Int J Hematol. 2004 Jun;79(5):420-33. Review.

PMID:
15239391
[PubMed - indexed for MEDLINE]
6.
7.

Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.

Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M.

Cell Cycle. 2006 Oct;5(19):2223-9. Epub 2006 Oct 1.

PMID:
16969080
[PubMed - indexed for MEDLINE]
Free Article
8.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
[PubMed - indexed for MEDLINE]
9.

NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.

Lounnas N, Frelin C, Gonthier N, Colosetti P, Sirvent A, Cassuto JP, Berthier F, Sirvent N, Rousselot P, Dreano M, Peyron JF, Imbert V.

Int J Cancer. 2009 Jul 15;125(2):308-17. doi: 10.1002/ijc.24294.

PMID:
19378338
[PubMed - indexed for MEDLINE]
10.

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.

Cancer Res. 2005 Oct 15;65(20):9436-44.

PMID:
16230407
[PubMed - indexed for MEDLINE]
Free Article
11.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
[PubMed - indexed for MEDLINE]
12.

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.

PMID:
17545631
[PubMed - indexed for MEDLINE]
Free Article
13.

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J.

Semin Oncol. 2008 Feb;35(1 Suppl 1):S1-17; quiz S18-20. doi: 10.1053/j.seminoncol.2007.12.002. Review.

PMID:
18346528
[PubMed - indexed for MEDLINE]
14.

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

Chen R, Gandhi V, Plunkett W.

Cancer Res. 2006 Nov 15;66(22):10959-66.

PMID:
17108134
[PubMed - indexed for MEDLINE]
Free Article
15.

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, Ritter M, Hochhaus A, Müller R, Eilers M, Schmidt M, Neubauer A.

Blood. 2004 May 1;103(9):3480-9. Epub 2003 Dec 4.

PMID:
14656881
[PubMed - indexed for MEDLINE]
Free Article
16.

Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.

Bonovolias ID, Tsiftsoglou AS.

Oncol Res. 2009;17(11-12):535-47.

PMID:
19806784
[PubMed - indexed for MEDLINE]
17.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J.

Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.

PMID:
17179059
[PubMed - indexed for MEDLINE]
18.

Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.

Mughal TI, Goldman JM.

Front Biosci. 2006 Jan 1;11:209-20. Review.

PMID:
16146726
[PubMed - indexed for MEDLINE]
19.

Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?

Doggrell SA.

Expert Opin Investig Drugs. 2005 Aug;14(8):1063-6. Review.

PMID:
16050798
[PubMed - indexed for MEDLINE]
20.

Nilotinib therapy in chronic myelogenous leukemia.

Quintas-Cardama A, Cortes J.

Drugs Today (Barc). 2007 Oct;43(10):691-702. Review.

PMID:
17987222
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk